Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in the following...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced eight studies to be presented at the 2022 American Society of Clinical...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced the commercial availability of the expanded Invitae Pharmacogenomics (PGx)...
— Executing toward 2022 plan, generating near 20% revenue growth, with $885 million in ending cash*, an annualized burn reduction of greater than...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2022 financial results on ...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced the full commercial launch of its Neurodevelopmental Disorders (NDD)...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of Invitae Digital Health—a connected digital health platform...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced full access to its Personalized Cancer Monitoring (PCMTM) platform to help...
Invitae (NYSE: NVTA), a leading medical genetics company, today released its 2022 Environmental, Social and Governance (ESG) Report summarizing the...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and year ended...
Ведущий производитель в области медицинской генетики Invitae (NYSE: NVTA) выводит на европейский рынок тест-наборы для диагностики рака FusionPlex...
Invitae (NYSE : NVTA), société leader dans le domaine de la génétique médicale, annonce aujourd'hui la disponibilité de FusionPlex Dx® et LiquidPlex...
Invitae (NYSE: NVTA), ein führendes Unternehmen im Bereich der medizinischen Genetik, gab heute die Verfügbarkeit von FusionPlex Dx® und LiquidPlex...
Invitae (NYSE: NVTA), czołowa spółka z branży genetyki medycznej, poinformowała dzisiaj o udostępnieniu w Europie testów FusionPlex Dx® i LiquidPlex...
Nové diagnostické soupravy in vitro pomáhají pacientům v EU v boji proti rakovině SAN FRANCISCO, 16. února 2022 /PRNewswire/ – Invitae (NYSE: NVTA),...
Spoločnosť Invitae (NYSE: NVTA), popredná spoločnosť v oblasti lekárskej genetiky, dnes oznámila dostupnosť produktov FusionPlex Dx® a LiquidPlex Dx™ ...
Invitae (NYSE: NVTA), una empresa líder en genética médica, anunció hoy la disponibilidad de FusionPlex Dx® y LiquidPlex Dx™ en Europa, parte de sus...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of FusionPlex Dx® and LiquidPlex Dx™ in Europe, part of...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2021...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in virtual ...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, applauds the Biden Administration's announcement to reignite the Cancer...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2021 revenue, billable volume and...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, chief executive officer, will present...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30,...
Investigators from Northwestern University Feinberg School of Medicine and Invitae (NYSE: NVTA), a medical genetics company, will present the results ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.